---
document_datetime: 2025-11-21 15:06:16
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/obizur-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: obizur-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6722966
conversion_datetime: 2025-12-24 17:22:57.593863
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## OBIZUR

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 16/10/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000304597   | variations.   |
|---------------------|---------------|

<div style=\"page-break-after: always\"></div>

|                                            | substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                        |            |            |                                  |                                                                                                                                                                                                                                                                      |
|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000290083      | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted | 21/08/2025 | N/A        |                                  |                                                                                                                                                                                                                                                                      |
| Renewal - 5 year / EMA/R/0000248614        | - Renewal - Accepted                                                                                                                                                                                                                                                                                                | 19/06/2025 | 14/08/2025 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Obizur in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| Annual reassessment - H / EMA/S/0000246111 |                                                                                                                                                                                                                                                                                                                     | 22/05/2025 |            |                                  |                                                                                                                                                                                                                                                                      |